Sonnet BioTherapeutics Holdings Inc. [NASDAQ: SONN] jumped around 1.2 points on Friday, while shares priced at $4.11 at the close of the session, up 41.24%. The company report on July 20, 2020 that Sonnet Biotherapeutics Announces Positive Preclinical Results from an Initial Efficacy Study Exploring the Combination of Granulocyte-Macrophage Colony-Stimulating Factor with Interleukins 18 and 12.
Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing innovative targeted biologic drugs with enhanced mono or bispecific mechanisms, announced today that it has completed initial preclinical proof-of-concept work with both GMcSF and IL-18 and with GMcSF and IL-12 in a xenograft mouse model of melanoma. This study was designed to evaluate preclinical activity of the concomitantly administered cytokines as FHAB-derived molecules, using Sonnet’s Fully Human Albumin Binding (FHAB) technology, in several groups of tumor-bearing mice. Sonnet’s FHAB-derived drug candidates all showed statistically significant reduction in tumor growth compared to placebo and when compared to cytokines not derived from the Company’s platform.
The study included nine mice per active group and 12 mice in the placebo group. The Company administered a single dose as a conservative method for therapeutic lead selection. The table below summarizes the data after six days of administration of a single dose, in tumor bearing mice with an average initial cancer tumor volume of approximately 100 mm3. P values were generated for between group comparisons (treatment vs placebo) of reduction in tumor growth.
Sonnet BioTherapeutics Holdings Inc. stock is now -73.21% down from its year-to-date (YTD) trading value. SONN Stock saw the intraday high of $7.89 and lowest of $3.77 per share. The company’s 52-week high price is 54.60, which means current price is +63.10% above from all time high which was touched on 03/19/20.
Compared to the average trading volume of 529.59K shares, SONN reached a trading volume of 130765641 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Sonnet BioTherapeutics Holdings Inc. [SONN]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SONN shares is $7.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SONN stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Average True Range (ATR) for Sonnet BioTherapeutics Holdings Inc. is set at 0.65, with the Price to Sales ratio for SONN stock in the period of the last 12 months amounting to 0.96.
How has SONN stock performed recently?
Sonnet BioTherapeutics Holdings Inc. [SONN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 40.75. With this latest performance, SONN shares gained by 12.30% in over the last four-week period, additionally sinking by -75.31% over the last 6 months – not to mention a drop of -78.07% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SONN stock in for the last two-week period is set at 63.84, with the RSI for the last a single of trading hit 71.81, and the three-weeks RSI is set at 55.41 for Sonnet BioTherapeutics Holdings Inc. [SONN]. The present Moving Average for the last 50 days of trading for this stock 3.68, while it was recorded at 3.04 for the last single week of trading, and 11.25 for the last 200 days.
Sonnet BioTherapeutics Holdings Inc. [SONN]: Deeper insight into the fundamentals
Sonnet BioTherapeutics Holdings Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.10 and a Current Ratio set at 0.10.
Earnings analysis for Sonnet BioTherapeutics Holdings Inc. [SONN]
With the latest financial reports released by the company, Sonnet BioTherapeutics Holdings Inc. posted -8.84/share EPS, while the average EPS was predicted by analysts to be reported at -8.06/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -9.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SONN.
Insider trade positions for Sonnet BioTherapeutics Holdings Inc. [SONN]
There are presently around $0 million, or 0.50% of SONN stock, in the hands of institutional investors. The top three institutional holders of SONN stocks are: UBS GROUP AG with ownership of 4,481, which is approximately New of the company’s market cap and around 9.40% of the total institutional ownership; REILLY FINANCIAL ADVISORS, LLC, holding 2,313 shares of the stock with an approximate value of $10000.0 in SONN stocks shares; and SUNTRUST BANKS INC, currently with $6000.0 in SONN stock with ownership of nearly New of the company’s market capitalization.
9 institutional holders increased their position in Sonnet BioTherapeutics Holdings Inc. [NASDAQ:SONN] by around 10,238 shares. Additionally, 3 investors decreased positions by around 3,521 shares, while 5 investors held positions by with 714 shares. The mentioned changes placed institutional holdings at 13,045 shares, according to the latest SEC report filing. SONN stock had 8 new institutional investments in for a total of 10,134 shares, while 3 institutional investors sold positions of 3,521 shares during the same period.